Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Sep 4 - Sep 9
,
Phase 3 monotherapy results A post-hoc analysis of the phase 3 data showed cagrilintide 2.4 mg monotherapy produced 11.8% average body weight reduction versus 2.3% for placebo over 68 weeks
If symptoms persist beyond a few days or worsen, contacting a healthcare professional is important
The smaller quantity allows researchers to perform precise, lowvolume experiments and accurate peptide concentration studies
Let the vial sit at room temperature for 1520 minutes before adding water
US$ 22.99
US$ 26.86
US$ 22.39
